COVID-19: Implications for Managing Antiretroviral Therapy in Patients With HIV

In this collection of commentaries, expert faculty review the guidance and provide expert perspective on how to manage ART in patients with HIV during the COVID-19 pandemic; topics include maintaining stable ART, COVID-19 risk in persons with HIV, and switching ART.
Princy N. Kumar, MD, FIDSA, MACP
Paul E. Sax, MD
Renslow Sherer, MD
David A. Wohl, MD

ClinicalThought

The DHHS released interim guidance on special considerations during the COVID-19 pandemic for patients with HIV. Here’s my take on how these can be incorporated into practice to minimize patient risk.

Paul E. Sax, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 10, 2020 Expired: April 9, 2021

The DHHS recently released practical guidance on maintaining stable ART for patients with HIV during the COVID-19 pandemic. Here are some considerations for implementing this guidance.

Princy N. Kumar, MD, FIDSA, MACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 21, 2020 Expired: April 20, 2021

The DHHS guidance on managing care for persons with HIV during the COVID-19 pandemic recommends integrating telehealth and postponing routine visits. What does this mean for patients who are not stably suppressed? Here’s my experience.

David A. Wohl, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 14, 2020 Expired: August 13, 2021

Are PWH at risk of more severe COVID-19 illness? How should PWH protect themselves? Here’s what we know.

Renslow Sherer, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: October 12, 2020 Expired: October 11, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
Theratechnologies Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue